Pages that link to "Q46369982"

The following pages link to The triple monoaminergic reuptake inhibitor DOV 216,303 has antidepressant effects in the rat olfactory bulbectomy model and lacks sexual side effects (Q46369982):

Displaying 25 items.

• The effects of LPM570065, a novel triple reuptake inhibitor, on extracellular serotonin, dopamine and norepinephrine levels in rats (Q21132285) (← links)
• The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties (Q24633511) (← links)
• Current investigational drugs for major depression (Q28244223) (← links)
• Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties (Q28248325) (← links)
• The potential and limitations of DOV 216,303 as a triple reuptake inhibitor for the treatment of major depression: A microdialyis study in olfactory bulbectomized rats (Q28295236) (← links)
• SKF83959 is a novel triple reuptake inhibitor that elicits anti-depressant activity (Q28295413) (← links)
• Retracted: Suppression of Neuroinflammatory and Apoptotic Signaling Cascade by Curcumin Alone and in Combination with Piperine in Rat Model of Olfactory Bulbectomy Induced Depression (Q28486258) (← links)
• Serotonergic lesions of the periaqueductal gray, a primary source of serotonin to the nucleus paragigantocellularis, facilitate sexual behavior in male rats (Q34728923) (← links)
• Rodent models of treatment-resistant depression. (Q35580361) (← links)
• Differential BDNF Responses of Triple Versus Dual Reuptake Inhibition in Neuronal and Astrocytoma Cells as well as in Rat Hippocampus and Prefrontal Cortex (Q36147115) (← links)
• Effect of newly synthesized 1,2,4-triazino[5,6-b]indole-3-thione derivatives on olfactory bulbectomy induced depression in rats. (Q36752924) (← links)
• Emerging drugs for major depressive disorder (Q37564562) (← links)
• Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited (Q37891098) (← links)
• Contributions of animal models to the study of mood disorders. (Q38165755) (← links)
• Addiction-related effects of DOV 216,303 and cocaine: A comparative study in the mouse. (Q39299851) (← links)
• Exploring a post-traumatic stress disorder paradigm in Flinders sensitive line rats to model treatment-resistant depression II: response to antidepressant augmentation strategies (Q39333515) (← links)
• Molecular Mechanisms Underlying the Anti-depressant Effects of Resveratrol: a Review (Q39427752) (← links)
• Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors (Q39665539) (← links)
• Antidepressant-like activity of adhyperforin, a novel constituent of Hypericum perforatum L. (Q42726331) (← links)
• Synthesis and Pharmacological Characterization of Bicyclic Triple Reuptake Inhibitor 3-Aryl Octahydrocyclopenta[c]pyrrole Analogues (Q42730845) (← links)
• Restoration of serotonin neuronal firing following long-term administration of bupropion but not paroxetine in olfactory bulbectomized rats. (Q43186658) (← links)
• Exploring a post-traumatic stress disorder paradigm in Flinders sensitive line rats to model treatment-resistant depression I: bio-behavioural validation and response to imipramine (Q48043296) (← links)
• The triple reuptake inhibitor DOV216,303 exhibits limited antidepressant-like properties in the differential reinforcement of low-rate 72-second responding assay, likely due to dopamine reuptake inhibition (Q48371652) (← links)
• Toxicity effects of a novel potent triple reuptake inhibitor, LPM570065, on the fertility and early embryonic development in Sprague-Dawley rats (Q57805647) (← links)
• Acute, subchronic oral toxicity, and genotoxicity evaluations of LPM570065, a new potent triple reuptake inhibitor (Q90373319) (← links)